| 生物活性 | |||
|---|---|---|---|
| 靶点 | 
 | ||
| 描述 | GSK1324726A works as both a selective BET Bromodomain inhibitor with pIC50 values of 7.4, 7.1, 7 and 7.3 for BRD2, BRD3, BRD4 and BRDT, respectively, and a potent tetrahydroquinoline ApoA1 up-regulator. It inhibited the production of LPS-stimulated IL6 with pIC50 values of 7.3 and 6.4 in PBMC and HWB cells, respectively. Oral administration of GSK1324726A at doses of 3mg/kg and 10mg/kg significantly reduced expression of PAI-1 mRNA in a murine acute LPS challenge model. Intravenous injection with GSK1324726A at dose of 10mg/kg increased the ratio of survival of a murine septic shock model[3]. | ||
| 作用机制 | GSK1324726A binds to the acetyl-lysine pocket.[3] | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
| 1 mM 5 mM 10 mM | 2.30mL 0.46mL 0.23mL | 11.50mL 2.30mL 1.15mL | 22.99mL 4.60mL 2.30mL | 
| 参考文献 | 
|---|